發(fā)布時(shí)間：2018-09-01 20:31

【摘要】：研究目的:組蛋白去乙酰化酶抑制劑(HDACI)是一類在染色質(zhì)水平調(diào)控基因表達(dá)的化合物,其所調(diào)控的基因與細(xì)胞周期停滯,細(xì)胞分化及細(xì)胞凋亡等重要生物學(xué)效應(yīng)密切相關(guān)。HDACI對(duì)眾多實(shí)體器官和血液系統(tǒng)腫瘤中具有強(qiáng)大的抗腫瘤活性,因此圍繞HDACI的研究主要集中于腫瘤領(lǐng)域。新近研究發(fā)現(xiàn),HDACI具備改善自身免疫性疾病模型癥狀,調(diào)控固有免疫功能以及抑制促炎細(xì)胞因子表達(dá)等一系列免疫調(diào)節(jié)活性。T淋巴細(xì)胞作為免疫反應(yīng)的中心環(huán)節(jié),在炎癥免疫性疾病和移植免疫中發(fā)揮重要作用。然而HDACI對(duì)T淋巴細(xì)胞功能的調(diào)控作用和機(jī)制及其對(duì)移植排斥反應(yīng)的影響少有報(bào)道,其分子機(jī)制有待于進(jìn)一步闡明。我們通過設(shè)計(jì)體外和體內(nèi)實(shí)驗(yàn),研究組蛋白去乙�；敢种苿㏒AHA對(duì)T淋巴細(xì)胞增殖、活化和分化功能,基因表達(dá)調(diào)控和移植排斥反應(yīng)的影響,以探討HDACI在體外和體內(nèi)對(duì)T淋巴細(xì)胞的調(diào)控作用及分子機(jī)制。研究方法:(1)MACS法體外分選小鼠脾臟來源CD4~+和CD8~+T淋巴細(xì)胞,通過ConA或培養(yǎng)板包被的抗CD3/CD28活化,并加入不同濃度SAHA干預(yù),3H-TdR法檢測(cè)細(xì)胞增殖,FCM檢測(cè)T細(xì)胞活化標(biāo)志分子及細(xì)胞凋亡情況,熒光定量PCR檢測(cè)促炎細(xì)胞因子表達(dá),Western-blot分析NF-κB、NFAT等轉(zhuǎn)錄因子表達(dá)的變化。(2)CD4~+T細(xì)胞體外分選及活化同前,流式及熒光定量PCR檢測(cè)Foxp3表達(dá),分析SAHA對(duì)Treg分化的影響;MACS法分選Treg和Teff細(xì)胞,分別活化并給予SAHA干預(yù),熒光定量PCR檢測(cè)FOXP3表達(dá),分析SAHA對(duì)Treg體外擴(kuò)增,Teff轉(zhuǎn)化的作用;CFSE標(biāo)記的Teff與Treg按照不同比例混合并活化,流式檢測(cè)增殖情況以分析SAHA對(duì)Treg抑制功能的影響,并探討其分子機(jī)制。(3)體外誘導(dǎo)CD4~+T細(xì)胞向Th17分化,并加入不同濃度SAHA干預(yù),流式檢測(cè)IL-17A蛋白表達(dá),熒光定量PCR檢測(cè)Th17相關(guān)基因表達(dá)變化,分析SAHA調(diào)控Th17分化的分子機(jī)制。(4)構(gòu)建小鼠頸部異位心臟移植模型(BALB/C→C57),觀察單獨(dú)應(yīng)用SAHA及聯(lián)合雷帕霉素(RPM)對(duì)移植物存活期的影響,取心臟移植物進(jìn)行病理分析,熒光定量檢測(cè)移植物內(nèi)炎性因子表達(dá);移植后第7天流式檢測(cè)胸腺、脾臟、淋巴結(jié)中Treg的比例;過繼轉(zhuǎn)移研究SAHA在體內(nèi)對(duì)Teff的轉(zhuǎn)化作用;流式檢測(cè)SAHA對(duì)Treg抑制功能的影響;探討SAHA對(duì)移植排斥反應(yīng)的調(diào)控作用與分子機(jī)制。(5)檢測(cè)SAHA處理組和DMSO處理組小鼠脾臟來源Treg細(xì)胞活化前后HDACs表達(dá)情況,篩選調(diào)控Treg細(xì)胞分化的關(guān)鍵HDACs,構(gòu)建相應(yīng)siRNA轉(zhuǎn)染Jurkat細(xì)胞,熒光定量PCR檢測(cè)Treg相關(guān)基因表達(dá),驗(yàn)證HDACs對(duì)Treg細(xì)胞分化的調(diào)控作用。結(jié)果:(1)SAHA對(duì)T淋巴細(xì)胞增殖、活化和分化的影響: SAHA呈時(shí)間及劑量依賴性的抑制CD4~+和CD8~+T淋巴細(xì)胞增殖;高濃度SAHA顯著抑制CD25和NF-κB表達(dá),而CD69在活化后2h,6h和12h均無顯著改變,提示SAHA影響T細(xì)胞中后期活化;SAHA阻斷IL-2、IFN-γ、IL-12、TNF-α、和IL-10等促炎細(xì)胞因子表達(dá);SAHA呈時(shí)間及劑量依賴性的促進(jìn)T細(xì)胞凋亡。同時(shí)顯著抑制體外誘導(dǎo)的Th17分化,提示高濃度SAHA可通過干預(yù)T淋巴細(xì)胞活化和眾多促炎基因表達(dá)發(fā)揮免疫抑制作用。(2)SAHA在體外對(duì)Treg細(xì)胞的誘導(dǎo)作用:隨著SAHA濃度的增加, CD4~+Foxp3~+T細(xì)胞所占的比例顯著降低,高濃度SAHA顯著下調(diào)Foxp3基因表達(dá),而低濃度SAHA(0.1μM)輕度增加了Treg的比例,但沒有上調(diào)FOXP3表達(dá),流式檢測(cè)顯示低濃度SAHA選擇性誘導(dǎo)Teff細(xì)胞凋亡,從而間接增加了Treg比例。盡管熒光定量PCR檢測(cè)顯示SAHA在體外不能促進(jìn)Treg擴(kuò)增或Teff向Treg轉(zhuǎn)化,但SAHA可通過上調(diào)CTLA-4增強(qiáng)Treg的抑制功能。(3)SAHA對(duì)Th17分化的影響:流式檢測(cè)顯示SAHA(0.1-1μM)顯著抑制IL-17A表達(dá),低濃度SAHA顯著抑制IL-17A、IL-17F和STAT3表達(dá),而不影響RORγt,提示SAHA可能通過抑制STAT3通路抑制Th17分化。有趣的是,與對(duì)照組相比,SAHA處理后的Th17中FOXP3表達(dá)顯著上調(diào),顯示SAHA可能參與調(diào)控Treg和Th17平衡。(4)在小鼠頸部異位心臟移植模型中,載體對(duì)照組移植物在7天內(nèi)即發(fā)生排斥反應(yīng)而停跳,而50mg/kg SAHA顯著延長(zhǎng)移植物中期存活時(shí)間(MST)至16天,而低于治療劑量的RPM(0.1mg/kg)延長(zhǎng)移植物MST至10天,當(dāng)50mg/kg SAHA與低劑量RPM聯(lián)合應(yīng)用時(shí),顯著延長(zhǎng)移植物MST至26天;組織病理檢測(cè)顯示對(duì)照組伴隨著心肌結(jié)構(gòu)破壞和間質(zhì)細(xì)胞浸潤(rùn),SAHA處理組移植物心肌結(jié)構(gòu)仍完整,但間質(zhì)細(xì)胞浸潤(rùn)部分得到改善,而聯(lián)合用藥組既保持了心肌結(jié)構(gòu)完整又阻止了間質(zhì)細(xì)胞浸潤(rùn)。移植物檢測(cè)發(fā)現(xiàn)SAHA處理組Foxp3、CTLA-4、IL-10基因表達(dá)顯著上調(diào),CD11b、IL-17、INF-γ表達(dá)下調(diào),提示SAHA在體內(nèi)促進(jìn)Treg分化而抑制Th1和Th17分化。(5)SAHA處理組受者體內(nèi)胸腺、淋巴結(jié)和脾臟中Foxp3~+T細(xì)胞比例顯著升高,其抑制功能與對(duì)照相比顯著增強(qiáng);過繼轉(zhuǎn)移實(shí)驗(yàn)發(fā)現(xiàn)SAHA在體內(nèi)不能促進(jìn)外周CD4~+CD25~-T細(xì)胞轉(zhuǎn)化為CD4~+Foxp3~+Treg,這些結(jié)果表明SAHA在體內(nèi)增加胸腺來源的天然Treg數(shù)量,而非外周轉(zhuǎn)化;在IL-~(2-/-)小鼠受者移植模型中,50mg/kg SAHA無法延長(zhǎng)移植物存活時(shí)間,由于IL-2對(duì)Treg發(fā)育必不可少,這些結(jié)果提示Treg在SAHA介導(dǎo)的抗移植排斥作用中至關(guān)重要。(5)熒光定量PCR檢測(cè)顯示,HDAC1、HDAC2、HDAC3、HDAC7在Treg活化后顯著升高,但SAHA處理組與DMSO處理組之間無顯著性差異,而HDAC9在活化后顯著降低,SAHA處理組進(jìn)一步下調(diào)HDAC9表達(dá),二者之間具有顯著性差異,體外通過小siRNA干擾HDAC9可顯著上調(diào)Foxp3和CTLA4基因表達(dá),提示HDAC9在Treg發(fā)育過程中發(fā)揮重要作用。結(jié)論:本文探討了SAHA對(duì)T淋巴細(xì)胞功能和移植排斥反應(yīng)的調(diào)控作用及分子機(jī)制。SAHA被證實(shí)發(fā)揮多種T淋巴細(xì)胞調(diào)節(jié)功能。高濃度SAHA在體外顯著促進(jìn)T細(xì)胞凋亡,抑制T淋巴細(xì)胞增殖、活化和眾多促炎基因表達(dá)。而低濃度 SAHA顯著增強(qiáng)Treg的抑制功能并可能參與調(diào)控Treg和Th17平衡;體內(nèi)研究顯示SAHA通過增加胸腺來源Treg的數(shù)量和增強(qiáng)Treg的抑制功能而抑制急性排斥反應(yīng)的發(fā)生。而HDAC9可能對(duì)Treg分化和發(fā)揮抑制功能具有重要調(diào)控作用,這些結(jié)果提示SAHA在體內(nèi)和體外通過不同的機(jī)制調(diào)控Treg分化,而進(jìn)一步研究顯示HDAC9在Treg分化過程中發(fā)揮關(guān)鍵作用。本文證實(shí)了SAHA的抗移植排斥作用,并對(duì)其機(jī)制進(jìn)行淺析,為HDACI應(yīng)用于器官移植提供了一定的依據(jù)。
[Abstract]:Objective: Histone deacetylase inhibitors (HDACI) are a class of compounds that regulate gene expression at chromatin level. The genes regulated by HDACI are closely related to cell cycle arrest, cell differentiation and apoptosis. Recent studies have found that HDACI has a series of immunomodulatory activities, such as improving the symptoms of autoimmune disease models, regulating innate immune function and inhibiting the expression of pro-inflammatory cytokines. HDACI plays an important role in the epidemic. However, the regulatory effect and mechanism of HDACI on T lymphocyte function and its effect on transplant rejection are seldom reported, and its molecular mechanism needs further elucidation. Methods: (1) MacS method was used to isolate mouse spleen-derived CD4~+ and CD8~+ T lymphocytes in vitro. ConA or plate-coated anti-CD3/CD28 were activated and different concentrations of SAHA were added to interfere with the activation of CD3/CD28. Cell proliferation was detected, T cell activation markers and apoptosis were detected by FCM, pro-inflammatory cytokines were detected by fluorescence quantitative PCR, and transcription factors such as NF-kappa B and NFAT were analyzed by Western blot. Treg and Teff cells were selected by MACS and activated by SAHA respectively. The expression of FOXP3 was detected by fluorescence quantitative PCR, and the effects of SAHA on Treg proliferation and Teff transformation were analyzed. CFSE-labeled Teff and Treg were mixed and activated in different proportions. The proliferation of Treg cells was detected by flow cytometry to analyze the effect of SAHA on Treg inhibition function and explore its molecular mechanism. CD4~+T cells were induced to differentiate into Th17 cells in vitro, and different concentrations of SAHA were added to interfere with it. IL-17A protein expression was detected by flow cytometry, Th17-related gene expression was detected by fluorescence quantitative PCR, and the molecular mechanism of SAHA regulating Th17 differentiation was analyzed. (4) A mouse model of heterotopic heart transplantation was established (BALB/C C57), and SAHA and rapamycin (RP) were used alone. M) Effect of SAHA on graft survival, pathological analysis of heart grafts, quantitative detection of inflammation factor expression in grafts by fluorescence, flow cytometry of Treg in thymus, spleen and lymph nodes on the 7th day after transplantation, adoptive metastasis study of the effect of SAHA on Teff in vivo, flow cytometry of SAHA on Treg inhibition function; (5) To detect the expression of HDACs in spleen-derived Treg cells of SAHA and DMSO treated mice before and after activation, screen the key HDACs that regulate the differentiation of Treg cells, construct the corresponding siRNA to transfect Jurkat cells, detect the expression of Treg-related genes by fluorescence quantitative PCR, and verify the differentiation of Treg cells by HDACs. Results: (1) The effects of SAHA on T lymphocyte proliferation, activation and differentiation: SAHA inhibited the proliferation of CD4~+ and CD8~+ T lymphocytes in a time-and dose-dependent manner; high concentration of SAHA significantly inhibited the expression of CD25 and NF-kappa B, while CD69 did not change significantly at 2, 6 and 12 hours after activation, suggesting that SAHA affected the late activation of T cells; SAHA blocked IL-2. SAHA promoted T cell apoptosis in a time-and dose-dependent manner. SAHA significantly inhibited Th17 differentiation in vitro, suggesting that high concentration of SAHA could exert immunosuppressive effect by interfering with T lymphocyte activation and expression of many pro-inflammatory genes. (2) SAHA could induce Treg cells in vitro. Function: With the increase of SAHA concentration, the percentage of CD4~+Foxp3~+T cells decreased significantly, the expression of Foxp3 gene was significantly down-regulated by high concentration of SAHA, but Treg was slightly increased by low concentration of SAHA (0.1 mu), but FOXP3 expression was not up-regulated. Flow cytometry showed that low concentration of SAHA selectively induced Teff cell apoptosis, thus indirectly increasing Treg ratio. Although fluorescence quantitative PCR assay showed that SAHA could not promote Treg amplification or Teff to Treg transformation in vitro, SAHA could enhance Treg inhibition by up-regulating CTLA-4. (3) The effect of SAHA on Th17 differentiation: Flow cytometry showed that SAHA (0.1-1 muM) significantly inhibited the expression of IL-17A, IL-17F and STAT3, but not ROR. Gamma t, suggesting that SAHA may inhibit Th17 differentiation by inhibiting STAT3 pathway. Interestingly, compared with the control group, FOXP3 expression was significantly up-regulated in Th17 after SAHA treatment, suggesting that SAHA may be involved in regulating the balance of Treg and Th17. (4) In a mouse model of heterotopic heart transplantation in the neck, the graft in the carrier control group stopped beating within 7 days after rejection. 50 mg/kg SAHA significantly prolonged the graft medium-term survival (MST) to 16 days, while RPM (0.1 mg/kg) at lower doses prolonged the graft MST to 10 days. When 50 mg/kg SAHA was combined with low-dose RPM, the graft MST was significantly prolonged to 26 days. Histopathological examination showed that the control group was accompanied by myocardial structural damage and interstitial cell infiltration at SAHA site. The results showed that the expression of Foxp3, CTLA-4, IL-10 and CD11b, IL-17, INF-gamma were significantly up-regulated and down-regulated in SAHA treatment group, suggesting that SAHA could promote Treg differentiation in vivo. (5) The percentage of Foxp3~+ T cells in thymus, lymph nodes and spleen of SAHA treated recipients was significantly increased, and the inhibition function of Foxp3~+ T cells was significantly enhanced compared with the control group. The adoptive metastasis experiment showed that SAHA could not promote the transformation of peripheral CD4~+CD25~-T cells into CD4~+Foxp3~+ Treg in vivo, which indicated that SAHA increased the percentage of thymus in vivo. In the IL-~ (2-/-) mouse recipient transplantation model, 50 mg/kg SAHA could not prolong the survival time of the graft, because IL-2 was essential to the development of Treg, these results suggest that Treg plays an important role in SAHA-mediated anti-graft rejection. (5) Fluorescence quantitative PCR detection showed that HDAC1, HDAC2, HDAC3, HDAC 3, HDAC 7 increased significantly after Treg activation, but there was no significant difference between SAHA treatment group and DMSO treatment group. HDAC9 decreased significantly after activation. The expression of HDAC9 was further down-regulated by SAHA treatment group. There was significant difference between the two groups. HDAC9 gene expression was significantly up-regulated by interfering with HDAC9 by small siRNA in vitro, suggesting that HDAC9 was involved in Treg development. CONCLUSION: SAHA plays an important role in the regulation of T lymphocyte function and graft rejection. SAHA has been proved to play a variety of T lymphocyte regulatory functions. High concentration of SAHA significantly promotes T cell apoptosis, inhibits T lymphocyte proliferation, activates and promotes the expression of many inflammatory genes in vitro.
SAHA significantly enhances Treg inhibition and may be involved in regulating Treg and Th17 homeostasis; in vivo studies have shown that SAHA inhibits acute rejection by increasing the number of Treg derived from thymus and enhancing Treg inhibition. HDAC9 may play an important role in regulating Treg differentiation and inhibiting Treg function. These results suggest that SAHA may be involved in the regulation of Treg differentiation and inhibition in vivo. HDAC9 plays a key role in the differentiation of Treg. This paper confirms the anti-rejection effect of SAHA and analyzes its mechanism, which provides a basis for the application of HDACI in organ transplantation.
【學(xué)位授予單位】：第二軍醫(yī)大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2011
【分類號(hào)】：R392.1

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 傅鈺;張日俊;;3種發(fā)酵增效劑提高發(fā)酵豆粕肽產(chǎn)量能力的研究[J];飼料工業(yè);2011年15期

2 高峰;張愛民;楊季紅;耿艷;馬芳;;丙戊酸鈉對(duì)人肝癌細(xì)胞系SMMC-7721增殖及HPA、PCNA表達(dá)的影響[J];河北醫(yī)藥;2012年10期

3 高峰;楊季紅;張愛民;馬芳;康然;;丙戊酸鈉逆轉(zhuǎn)組蛋白低乙�；綄�(duì)肝癌細(xì)胞侵襲轉(zhuǎn)移的體外實(shí)驗(yàn)研究[J];河北醫(yī)藥;2012年12期

4 李娜;于世英;;丙戊酸鈉誘導(dǎo)Siha細(xì)胞周期阻滯的實(shí)驗(yàn)觀察[J];中華腫瘤防治雜志;2009年11期

5 謝建輝;顧建新;;C型凝集素[J];生命科學(xué);2011年06期

6 劉岑岑;任嬌艷;趙謀明;;超聲和均質(zhì)對(duì)蕓豆凝集素粗提物的影響[J];食品工業(yè)科技;2012年01期

7 王政;譚小力;張志燕;顧守來;李冠英;;甘藍(lán)型油菜表皮特異硫蛋白(ESP)的序列分析及其誘導(dǎo)表達(dá)[J];食品科學(xué);2012年07期

8 代景泉,蔡耘,錢小紅;蛋白質(zhì)糖基化分析方法及其在蛋白質(zhì)組學(xué)中的應(yīng)用[J];生物技術(shù)通訊;2005年03期

9 劉曉秋;羅秋華;鄒亞偉;唐惠瓊;;白血病患兒尿淀粉酶糖鏈異常、證型差異及相關(guān)機(jī)理[J];現(xiàn)代腫瘤醫(yī)學(xué);2008年06期

10 姚麗娟;唐欣昀;�；燮�;;棉花根際促生細(xì)菌的研究進(jìn)展[J];中國(guó)土壤與肥料;2009年06期

，

本文編號(hào)：2218271